Yogesh Vaishnav, Laxmi Banjare, Shekhar Verma, Govind Sharma, Deepak Biswas, Arpan Tripathi, Afzal B. Shaik, Richie R. Bhandare, Arvinder Kaur, Kavya Manjunath
Yogesh Vaishnav1*, Laxmi Banjare2, Shekhar Verma3, Govind Sharma1, Deepak Biswas1, Arpan Tripathi1, Afzal B. Shaik4, Richie R. Bhandare5,6, Arvinder Kaur7, Kavya Manjunath8
1Faculty of Pharmaceutical Sciences, Shri Shankaracharya Technical Campus, Junwani, Bhilai, 490020.
2School of Pharmaceutical Sciences, Guru Ghasidas Central University, Bilaspur – 495009 (C.G.) India.
3University College of Pharmacy, Pt Deendayal Upadhyay Memorial Health Sciences and Ayush University, Raipur, Chhattisgarh 493661.
4St. Mary’s College of Pharmacy, St. Mary’s Group of Institutions Guntur, Affiliated to Jawaharlal Nehru Technological University Kakinada, Chebrolu, Guntur, Andhra Pradesh, 522212.
5Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Ajman University, Ajman, United Arab Emirates.
6Centre of Medical and Bio-allied Health Sciences Research, Ajman Uniersity, Ajman, United Arab Emirates.
7Department of Pharmaceutics, KLE College of Pharmacy, Bengaluru
Volume - 15,
Issue - 12,
Year - 2022
World is facing a new pandemic called covid-19SARS-CoV-2) since a year ago. Unfortunately there is no treatment for Covid 19 nowadays as well as no potential therapies has been developed to overcome from coronavirus pandemic. Some potential drug molecules with combination have ability to respond for covid19 virus. From the research it was found that the reduction of viral load can be treated with hydroxychloroquine and azithromycin combination. We evaluate the mode of interactions of hydroxychloroquine and azithromycin with the dynamic site of SARS-CoV-2 coronavirus main protease. Molecular Structure-based computational approach viz. molecular docking simulations were performed to scale up their affinity and binding fitness of the docked complex of novel SARS-CoV-2 coronavirus protease and hydroxychloroquine and azithromycin. The natural inhibitor N3 of novel SARS-CoV-2 coronavirus protease were exhibited highest affinity in terms of MolDock score (-167.203Kcal/mol), and hydroxychloroquine was found with lowest target affinity (-55.917 Kcal/mol).The amino acid residue cysteine 145 and histidine 41 is bound covalently and formed hydrogen bond interaction with SARS-CoV-2 inhibitor known as inhibitor N3 as such, hydroxychloroquine and azithromycin also formed hydrogen bond interaction. The binding patterns of the inhibitor N3 of SARS-CoV-2 coronavirus main protease could be used as a guideline for medicinal chemist to explore their SARS-CoV-2 inhibitory potential.
Cite this article:
Yogesh Vaishnav, Laxmi Banjare, Shekhar Verma, Govind Sharma, Deepak Biswas, Arpan Tripathi, Afzal B. Shaik, Richie R. Bhandare, Arvinder Kaur, Kavya Manjunath. Computational Method on Hydroxychloroquine and Azithromycin for SARS-CoV-2: Binding Affinity Studies. Research Journal of Pharmacy and Technology2022; 15(12):5467-2. doi: 10.52711/0974-360X.2022.00922
Yogesh Vaishnav, Laxmi Banjare, Shekhar Verma, Govind Sharma, Deepak Biswas, Arpan Tripathi, Afzal B. Shaik, Richie R. Bhandare, Arvinder Kaur, Kavya Manjunath. Computational Method on Hydroxychloroquine and Azithromycin for SARS-CoV-2: Binding Affinity Studies. Research Journal of Pharmacy and Technology2022; 15(12):5467-2. doi: 10.52711/0974-360X.2022.00922 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-12-16
1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020 Feb 17: 4 doi.org/10.1016/j.ijantimicag.2020.105924
2. Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence”. Int J Antimicrob Agents. doi.org/10.1016/j.ijantimicag.2020.105948
3. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-atthe-media-briefing-on-covid-19-11-march-2020.
4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. doi.org/10.1001/jama.2020.2648
6. Zhenming Jin, Xiaoyu Du, […]Haitao Yang Structure of Mpro from COVID-19 virus and discovery of its inhibitors, Nature. doi.org/10.1038/s41586-020-2223
7. Omrani AS, Saad MM, Baig K, Bahloul A, Abdul-Matin M, Alaidaroos AY, et al. Ribavirin and interferonalfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.Lancet Infect Dis 2014; 14: 1090-5. doi.org/10.1016/S1473-3099(14)70920-X
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 2020; 395: 497-506.doi.org/10.1016/S0140-6736 (20)30183-5
9. Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020 Feb 15:105923. doi.org/10.1016/j.ijantimicag.2020.105923.
10. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. doi.org/ 10.1016/j.ijantimicag.2020.105932
11. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquineeffectivelyinhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res2020; 30:269–71.doi.org/10.1038/s41422-020-0282-0.
12. Al-Bari AA. Targeting endosomal acidification by chloroquine analogs as apromising strategy for the treatment of emerging viral diseases. PharmacolResPerspect 2017; 5: doi.org/10.1002/prp2.293
13. Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, et al. Design and synthesisof hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem 2006; 49:2845-2849. doi.org/10.1021/jm0601856
14. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016 Jun;123 (6):1386-94. Doi.org/10.1016/j.ophtha.2016.01.058.
15. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity andProjection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. Doi.org/10.1093/cid/ciaa237
16. Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, et al. Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: A randomized clinical trial. JAMA. 2015 Nov 17; 314(19):2034-2044. doi.org/10.1001/jama.2015.13896
17. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as atreatment of COVID-19: results of an open-label non-randomised clinical trial. Int J Antimicrob Agents 2020. Doi.org/10.1016/j.ijantimicag.2020.105949
18. Yogesh Vaishnav, Aloksingh Thakur, Chanchal Deep Kaur, Shekhar Verma, Achal Mishra, Sanmati Kumar Jain , Piyush Ghode. QSAR Analysis of some N, N-diphenyl urea derivatives as CCR5 Receptor Antagonist. Research J. Pharm. and Tech 2018; 11(9): 3802-3810.doi.org/10.5958/0974-360X.2018.00697.2
19. Navjot Kaur, Monika, Kulwinder Singh. 3D-QSAR and Molecular Docking Studies of N-(2-Aminophenyl)-Benzamide Derivatives as Inhibitors of HDAC2. Research J. Pharm. and Tech. 7(7): July 2014 Page 760-770. Doi.org/10.5958/0974-360X
20. E. Shanmugapriya, V. Ravichandiran, M. Vijey Aanandhi. Molecular docking studies on naturally occurring selected flavones against protease enzyme of Dengue virus. Research J. Pharm. and Tech. 2016; 9(7):929-932.doi.org/:10.5958/0974-360X.2016.00178.5
21. Neenapriya Prasad Nair, Josna Joy, Silpa. S. Kumar, S.Sathianarayanan, Asha Ashokan Manakadan, Saranya T.S. In-silico Docking Studies of Coumarin Derivatives as Caspase 8 and PDE4 Antagonist. Research J. Pharm. and Tech 2016; 9(12):2199-2204. doi.org/10.5958/0974-360X.2016.00445.5
22. Pavlo V. Zadorozhnii, Vadym V. Kiselev, Anastasia E. Titova, Aleksandr V. Kharchenko, Ihor O. Pokotylo, Oxana V. Okhtina. Molecular Docking Studies of N-5-Aryl-1, 3, 4-oxadiazolo-2, 2-dichloroacet-amidines as Inhibitors of Enoyl-ACP Reductase Mycobacterium tuberculosi. Research J. Pharm. and Tech. 2017; 10(4): 1091-1097.doi.org/10.5958/0974-360X.2017.00198.6
23. Animisha Mokkapati, Radha Krishna Nagumantri, Chinna Babu Pydi, Ramakrishna Chintala, Satyanarayana Rentala. Docking Studies of Piperine-Vitamin a Conjugate to Study the Increase in Bioavailability of Vitamin A. Research J. Pharm. and Tech. 2017; 10(7): 2189-2193.doi.org/10.5958/0974-360X.2017.00386.9
24. T. Arunkumar, Ann Feba Ebby, G. Narendrakumar. Docking studies of Benzisoxazole analogues in White Spot Syndrome Virus. Research J. Pharm. and Tech. 2017; 10(8): 2497-2500. Doi.org/10.5958/0974-360X.2017.00441.3
25. Jeyabaskar Suganya, Viswanathan T, Mahendran Radha, Nishandhini Marimuthu. In silico Molecular Docking studies to investigate interactions of natural Camptothecin molecule with diabetic enzymes. Research J. Pharm. and Tech. 2017; 10(9): 2917-2922. Doi.org/10.5958/0974-360X.2017.00515.7
26. H. S. Baul, M. Rajiniraja. Molecular Docking Studies of Selected Flavonoids on Inducible Nitric Oxide Synthase (INOS) in Parkinson’s Disease. Research J. Pharm. and Tech 2018; 11(8): 3685-3688. doi.org/10.5958/0974-360X.2018.00676.5
27. Naresh Panigrahi, Swastika Ganguly, Jagadeesh Panda. Synthesis, Antimicrobial Evaluation and Molecular Docking Studies of Novel Oxazolidinone-Thiophene Chalcone Hybrid Derivatives. Research J. Pharm. and Tech 2018; 11(12): 5611-5622. doi.org/10.5958/0974-360X.2018.01019.3